Liquidia Reports Q3 2026 Growth Driven by YUTREPIA Sales and Legal Settlement
Liquidia Corporation (LQDA) reported strong third-quarter results for 2026, highlighted by a 31% sequential increase in net product sales to $222.7 million. This growth was primarily driven by increased volume of its product YUTREPIA. Despite the surge in revenue, the company recorded a one-time litigation settlement charge of $389.7 million to resolve all pending legal disputes with United Therapeutics. The settlement is intended to eliminate legal uncertainty regarding the commercial availability of YUTREPIA for PH-ILD treatments. Management confirmed that the company's cash position remains sufficient to cover both planned operational objectives and the multi-installment settlement obligations through April 2027. Operational metrics remain robust, with a patient conversion rate exceeding 87% and expanding prescriber bases.
Topics: earnings report EBITDA litigation settlement revenue growth